Meta Description:
Subtitle:
TLDRs:
- SKYE stock slipped as nimacimab obesity study advanced toward Phase 2b
- Skye launched higher-dose CBeyond cohorts ahead of Q4 clinical data
- Nimacimab showed durable weight-loss benefits with semaglutide use
- Skye reported $17.1 million cash while expanding obesity pipeline
- SKYE advanced subcutaneous delivery strategy for obesity treatment
Skye Bioscience (SKYE) stock traded at $0.8233 on Tuesday afternoon, declining 6.44% during market hours. The biotechnology company reported first-quarter 2026 financial results while advancing its obesity treatment program. The company also expanded clinical development activities for nimacimab ahead of a planned Phase 2b study.
Skye Bioscience, Inc., SKYE
Skye Bioscience continues developing next-generation therapies targeting G-protein-coupled receptors for obesity and metabolic conditions. The company focuses on nimacimab, an antibody designed to inhibit CB1 activity outside the brain. Furthermore, the therapy is being tested alongside GLP-1 treatments including Wegovy.
Management advanced several milestones during the quarter and maintained its 2026 development timeline. The company initiated enrollment for the CBeyond Expansion Study and completed formulation compatibility work. In addition, Skye continued planning for larger late-stage obesity studies.
CBeyond Expansion Study Moves Forward
Skye launched Cohort 1 of the CBeyond Expansion Study during the first quarter of 2026. The cohort evaluates nimacimab 400 mg intravenous dosing against placebo over 16 weeks. Patients will also complete a 12-week follow-up period after treatment ends.
The study uses a randomized 3:1 design and targets higher drug exposure levels. Skye plans to use the data for dose selection in a future Phase 2b study. The company expects topline data during the fourth quarter of 2026.
The Cohort Review Committee plans to review available safety data on May 18, 2026. The committee will decide whether Cohort 2 enrollment can begin safely. Cohort 2 will test nimacimab 600 mg intravenous dosing against placebo.
Nimacimab Data Supports Combination Obesity Strategy
Previous CBeyond data showed improved weight-loss outcomes when nimacimab was combined with semaglutide. Patients achieved an additional 3% weight-loss benefit compared with semaglutide alone after 26 weeks. The combination also improved waist circumference and lean-to-fat mass ratios.
An interim 52-week analysis showed 22.3% average weight loss among patients receiving nimacimab and semaglutide together. The study also reported no weight-loss plateau at the review stage. Furthermore, the therapy demonstrated a favorable tolerability profile during testing.
Skye reported no nimacimab-linked neuropsychiatric safety signal during the study period. The company also observed no added gastrointestinal burden when paired with semaglutide. During follow-up, participants showed lower weight regain compared with semaglutide-only treatment.
The company believes nimacimab may complement existing incretin therapies instead of competing directly with them. Skye targets patients requiring additional weight reduction or stronger metabolic control. The strategy also addresses patients limited by GLP-1 dosing tolerability.
Financial Results and Development Planning
Skye ended the first quarter with $17.1 million in cash and short-term investments. The company expects current capital to support operations through the fourth quarter of 2026. Projected funding excludes future Phase 2b clinical study costs.
Research and development expenses reached $7.9 million during the quarter. The figure increased from $7.2 million reported during the same period last year. Higher manufacturing, clinical trial, and consulting costs drove the increase.
General and administrative expenses totaled $4.7 million during the quarter. Net loss widened to $12.5 million compared with $11.1 million one year earlier. Meanwhile, stock-based compensation expense declined from $2.2 million to $1.5 million.
Skye also continued development work involving Halozyme Therapeutics ENHANZE technology. The company completed compatibility studies supporting high-volume subcutaneous delivery for nimacimab. Skye advanced work on high-concentration formulations to reduce injection volume and improve patient administration.
The company expects several milestones during 2026, including completion of enrollment for both expansion cohorts. Skye also plans to finalize its Phase 2b trial design during the fourth quarter. The company aims to strengthen nimacimab’s position within the expanding obesity treatment market.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
